Cargando…
Effects of SGLT2 inhibitor on tumor‐releasing chemokines/cytokines in Hep3B and Huh7 cells
(a) Summary for SGLT2i‐induced alterations in 48 chemokines/cytokines in Hep3B and Huh7 cells. (b) SGLT2i‐induced changes in the medium CXCL1 level (each n = 4). (c) SGLT2i‐induced changes in the medium CXCL8 level (each n = 4). (d) SGLT2i‐induced changes in the medium CXCL10 level (each n = 4), (e)...
Autores principales: | Nakano, Dan, Kawaguchi, Takumi, Tsutsumi, Tsubasa, Hayakawa, Masako, Yoshio, Sachiyo, Koga, Hironori, Torimura, Takuji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wiley Publishing Asia Pty Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9021706/ https://www.ncbi.nlm.nih.gov/pubmed/35475201 http://dx.doi.org/10.1002/jgh3.12730 |
Ejemplares similares
-
Effects of canagliflozin on growth and metabolic reprograming in hepatocellular carcinoma cells: Multi-omics analysis of metabolomics and absolute quantification proteomics (iMPAQT)
por: Nakano, Dan, et al.
Publicado: (2020) -
Hepatic expression of sodium–glucose cotransporter 2 (SGLT2) in patients with chronic liver disease
por: Nakano, Dan, et al.
Publicado: (2022) -
MAFLD enhances clinical practice for liver disease in the Asia-Pacific region
por: Kawaguchi, Takumi, et al.
Publicado: (2022) -
Effects of In-Hospital Exercise on Frailty in Patients with Hepatocellular Carcinoma
por: Tsuchihashi, Jin, et al.
Publicado: (2021) -
Effects of interleukin-17 inhibitors on hepatic fibrosis index in patients with psoriasis and metabolic dysfunction-associated fatty liver disease: Directed acyclic graphs
por: Takamura, Saori, et al.
Publicado: (2022)